Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer

Ahmad A. Tarhini, Imran Rafique, Theofanis Floros, Phu Tran, William E. Gooding, Liza C. Villaruz, Timothy F. Burns, David M. Friedland, Daniel P. Petro, Mariya Farooqui, Jose Gomez-Garcia, Autumn Gaither-Davis, Sanja Dacic, Athanassios Argiris, Mark A. Socinski, Laura P. Stabile, Jill M. Siegfried

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

BACKGROUND: Activation of the mesenchymal-epidermal transition factor (MET) tyrosine kinase and its ligand, hepatocyte growth factor (HGF), is implicated in resistance to epidermal growth factor receptor (EGFR) inhibitors. In this phase 1/2 trial, rilotumumab (an anti-HGF antibody) combined with erlotinib was evaluated in patients with metastatic, previously treated non–small cell lung cancer. METHODS: In phase 1, a dose de-escalation design was adopted with rilotumumab starting at 15 mg/kg intravenously every 3 weeks and oral erlotinib 150 mg daily. In phase 2, the disease control rate (DCR) (according to Response Evaluation Criteria in Solid Tumors) of the combination was evaluated using a Simon 2-stage design. The biomarkers examined included 10 plasma-circulating molecules associated with the EGFR and MET pathways. RESULTS: Without indications for de-escalation, the recommended phase 2 dose was dose level 0. Overall, 45 response-evaluable patients were enrolled (13 with squamous carcinoma, 32 with adenocarcinoma; 2 had confirmed EGFR mutations, 33 had confirmed wild-type [WT] EGFR, and 7 had KRAS mutations). The DCR for all patients was 60% (90% confidence interval [CI], 47.1%-71.3%). Median progression-free survival was 2.6 months (90% CI, 1.4-2.7 months), and median overall survival was 6.6 months (90% CI, 5.6-8.9 months). Among patients with WT EGFR, the DCR was 60.6% (90% CI, 46.3%-73.3%), median progression-free survival was 2.6 months (90% CI, 1.4-2.7 months), and median overall survival was 7.0 months (90% CI, 5.6-13.4 months). Elevated baseline levels of neuregulin 1 were associated with longer progression-free survival (hazard ratio, 0.41; 95% CI, 0.19-0.87), whereas elevated amphiregulin levels were associated with more rapid progression (hazard ratio, 2.14; 95% CI, 1.48-3.08). CONCLUSIONS: Combined rilotumumab and erlotinib had an acceptable safety profile, and the DCR met the prespecified criteria for success. In the EGFR WT group, the DCR exceeded published reports for erlotinib alone. High circulating levels of neuregulin 1 may indicate sensitivity to this combination. Cancer 2017;123:2936–44.

Original languageEnglish (US)
Pages (from-to)2936-2944
Number of pages9
JournalCancer
Volume123
Issue number15
DOIs
StatePublished - Aug 1 2017

Bibliographical note

Funding Information:
This study was supported by a grant from Amgen and in part by a National Institutes of Health Specialized Programs of Research Excellence (SPORE) award in Lung Cancer (P50CA090440). The University of Pittsburgh Cancer Institute shared resources, which are supported in part by National Institutes of Health/National Cancer Institute P30CA047904, were used for this project. An award from the V Foundation for Cancer Research also was used for this project.

Keywords

  • amphiregulin
  • epidermal growth factor receptor (EGFR)
  • erlotinib
  • hepatocyte growth factor (HGF)
  • mesenchymal-epidermal transition factor (c-MET)
  • neuregulin 1
  • non–small cell lung cancer (NSCLC)
  • rilotumumab (AMG 102)

Fingerprint Dive into the research topics of 'Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer'. Together they form a unique fingerprint.

Cite this